Unknown

Dataset Information

0

Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.


ABSTRACT: The clinical steroidal selective estrogen receptor (ER) degrader (SERD), fulvestrant, is effective in metastatic breast cancer, but limited by poor pharmacokinetics, prompting the development of orally bioavailable, nonsteroidal SERDs, currently in clinical trials. These trials address local breast cancer as well as peripheral metastases, but patients with brain metastases are generally excluded because of the lack of blood-brain barrier penetration. A novel family of benzothiophene SERDs with a basic amino side arm (B-SERDs) was synthesized. Proteasomal degradation of ER? was induced by B-SERDs that achieved the objectives of oral and brain bioavailability, while maintaining high affinity binding to ER? and both potency and efficacy comparable to fulvestrant in cell lines resistant to endocrine therapy or bearing ESR1 mutations. A novel 3-oxyazetidine side chain was designed, leading to 37d, a B-SERD that caused endocrine-resistant ER+ tumors to regress in a mouse orthotopic xenograft model.

SUBMITTER: Lu Y 

PROVIDER: S-EPMC7261373 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications


The clinical steroidal selective estrogen receptor (ER) degrader (SERD), fulvestrant, is effective in metastatic breast cancer, but limited by poor pharmacokinetics, prompting the development of orally bioavailable, nonsteroidal SERDs, currently in clinical trials. These trials address local breast cancer as well as peripheral metastases, but patients with brain metastases are generally excluded because of the lack of blood-brain barrier penetration. A novel family of benzothiophene SERDs with a  ...[more]

Similar Datasets

2023-10-25 | GSE240393 | GEO
| S-EPMC8345926 | biostudies-literature
| S-EPMC6072463 | biostudies-literature
| S-EPMC5913625 | biostudies-literature
| S-EPMC4221411 | biostudies-literature
| S-EPMC4779956 | biostudies-literature
| S-EPMC5786431 | biostudies-literature
2024-01-26 | PXD040478 | Pride
| S-EPMC9097292 | biostudies-literature
| S-EPMC7103015 | biostudies-literature